Discussion to: Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy using PlasmaBlade

Dr Basar Sareyyupoglu, MD, Dr Hiroo Takayama, MD

PII: S2666-2507(23)00283-3
DOI: https://doi.org/10.1016/j.xjtc.2023.08.007
Reference: XJTC 1472

To appear in: JTCVS Techniques

Received Date: 11 August 2023
Accepted Date: 11 August 2023

Please cite this article as: Sareyyupoglu B, Takayama H, Discussion to: Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy using PlasmaBlade, JTCVS Techniques (2023), doi: https://doi.org/10.1016/j.xjtc.2023.08.007.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2023 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery
Discussion to: Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy using PlasmaBlade

Presenter: Dr. Basar Sareyyupoglu, MD

Invited Discussant: Dr. Hiroo Takayama, MD

Corresponding Author: Dr. Basar Sareyyupoglu, MD

1. Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida

2. Cardiovascular Institute, New York Presbyterian/Columbia University, New York, NY

Correspondence: Dr. Basar Sareyyupoglu M.D.
Department of Cardiothoracic Surgery, Mayo Clinic, Florida 4500 San Pablo Road
Fax 904-953-7368.
E-mail: Sareyyupoglu.Basar@mayo.edu

Disclosures: None

Unidentified Speaker 1:

And the discussion will be opened up by Dr. Takayama from Columbia, New York.

Dr. Hiroo Takayama (New York, NY):

I would like to thank the society for allowing me to discuss this interesting paper, and I would like to congratulate Dr. Sareyyupoglu on developing this very interesting technique. Also, thank you for sharing the manuscript this morning.

Dr. Basar Sareyyupoglu (Jacksonville, FL):

I know.

Dr. Takayama:

The technique makes a lot of sense, and I might actually use them for the upcoming cases. Now, while minimum, there must be some tissue damage. One
of the many advantages of septal myectomy over septal ablation is minimum tissue injury with sharp resection. Related to this, I have the following questions. Did you experience any benefit from tissue degeneration, like, say, it became easy to graft the cutting edge?

Dr. Sareyyupoglu:

The benefit was practicality always. And when I started this, I wasn't like a 200-myectomy surgeon. Obviously, I was a fellow in Rochester for two years, helping Dr. Dearani and Schaff. I think I can say I have seen a little bit more with Dr. Dearani cases and minimum with Dr. Schaff cases. It's very difficult to see this surgery, to be honest with you. But Dr. Schaff started using cameras, but I wasn't in that era, right? Dr. Schaff probably had somebody holding the camera. People can understand me. And in my experience, some patients are more difficult anatomically. They are more muscular. It's difficult to manipulate. So, this gave me a little bit more pliable to, rather than the knife, digging slowly, and taking carefully and slowly those muscles. And in the long term, I think one of the things that, I don't know, the scarring with this type of technology, does it help? Obviously, we don't tell patients. They always ask, "Will this grow again?" Most of the time, I think Mayo Clinic data show if patients didn't get enough myectomy initial surgery, they are the ones that come back.

Dr. Takayama:

Yeah. Certainly, scar formation is a big possible concern. Have you had any data on long-term loop recorder or Holter EKG monitoring or long-term MRI?

Dr. Sareyyupoglu:

We didn't look specifically, but I don't remember anybody had a malignant arrhythmia that we got in trouble with.

Dr. Takayama:

Okay. And now, in the electrocautery, there is a cutting mode. In your understanding, is there any difference between PlasmaBlade and cutting mode of electrocautery?

Dr. Sareyyupoglu:

I think that slide that I showed you, still the transfer of the energy and the temperature, even use the cutting mode in both devices, there's a huge difference in temperature. This has a close to body temperature, 40 degrees to
70 degrees, depending on what setting you want to put. Electrocautery can go, even with the cutting function, you can reach up to 300 centigrade temperatures.

Dr. Takayama:

Finally, you had two VSDs. Do you think that might be related to the use of this blade? And I would like to, again, thank the society for this opportunity.

Dr. Sareyyupoglu:

Sure. I think VSDs happened apically. We both repaired them from the RVOT tract. No, I don't think it was the device. It was me. I think I was digging, and I wasn't satisfied. And I was more superior. I shouldn't be doing it and just, I learned my lesson. And it was in the first five patients, I remember.

Dr. Takayama:

Great. Thank you.

Unidentified Speaker 1:

Thank you. Moving forward. Our next speaker.